{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:56:10Z","timestamp":1793382970094,"version":"4.5.0"},"reference-count":22,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"unspecified","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,1,26]]},"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Spontaneous pneumomediastinum (SPNM) historically has been considered a poor prognostic factor in dermatomyositis\/polymyositis patients complicated with interstitial lung disease (ILD). However, there is a lack of actual data regarding the association between SPNM occurrence and mortality in dermatomyositis\/polymyositis patients. This study aimed to assess the association between SPNM occurrence and mortality in myositis patients with ILD according to antimelanoma differentiation-associated gene 5 (MDA5) antibody status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Dermatomyositis\/polymyositis patients with ILD who were hospitalised at five Japanese hospitals from 2016 to 2020 were included in this retrospective observational study. We collected data about baseline characteristics including myositis-specific autoantibodies, treatments, SPNM and death within 1\u2009year from therapy initiation or strengthening. Baseline characteristics and outcomes were compared between patients with and without SPNM (the SPNM group and the non-SPNM group, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 119 patients were analysed. SPNM occurred in 23 patients, and 15 patients died. Fifteen patients with SPNM were anti-MDA5 antibody positive. The mortality rate was significantly higher in the SPNM group (34.8%) than in the non-SPNM group (7.3%) (p=0.001). All deaths in the SPNM group occurred in anti-MDA5 antibody-positive patients (8\/15), whereas none of the anti-MDA5 antibody-negative patients in the SPNM group died (0\/8). In anti-MDA5 antibody-positive patients, the mortality rate was significantly higher in patients with SPNM occurrence (53.3%) than in those without SPNM occurrence (4.0%) (p=0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SPNM occurred more frequently in anti-MDA5 antibody-positive than in anti-MDA5 antibody-negative myositis patients. SPNM occurrence was associated with higher mortality risk, especially in anti-MDA5 antibody-positive patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002770","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T10:00:58Z","timestamp":1675936858000},"page":"e002770","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":25,"title":["Prognosis of spontaneous pneumomediastinum occurring in dermatomyositis or polymyositis patients with interstitial lung disease according to antimelanoma differentiation-associated gene 5 antibody status: a retrospective cohort study"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5300-1862","authenticated-orcid":false,"given":"Kazuya","family":"Abe","sequence":"first","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Furuta","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3645-937X","authenticated-orcid":false,"given":"Yoshihisa","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chiba Aoba Municipal Hospital, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, National Hospital Organization Shimoshizu Hospital, Yotsukaido, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9439-8918","authenticated-orcid":false,"given":"Shin-Ichiro","family":"Kagami","sequence":"additional","affiliation":[{"name":"Research Center for Allergy and Clinical Immunology, Asahi General Hospital, Asahi, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1682-9799","authenticated-orcid":false,"given":"Daiki","family":"Nakagomi","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Yamanashi Hospital, Chuo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1663-3518","authenticated-orcid":false,"given":"Taro","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0574-9611","authenticated-orcid":false,"given":"Kei","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8595-9381","authenticated-orcid":false,"given":"Hiroshi","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"2025090313041445000_9.1.e002770.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14368-1"},{"key":"2025090313041445000_9.1.e002770.2","doi-asserted-by":"publisher","DOI":"10.1097\/01.bor.0000179949.65895.53"},{"key":"2025090313041445000_9.1.e002770.3","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/acr.24646","article-title":"Prognosis and treatment of myositis-associated severe interstitial lung disease: a descriptive study using a nationwide inpatient database in Japan","volume":"74","author":"Furuya","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313041445000_9.1.e002770.4","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1506-7","article-title":"The predictive prognostic factors for polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"20","author":"Sugiyama","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025090313041445000_9.1.e002770.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.5.372"},{"key":"2025090313041445000_9.1.e002770.6","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2169\/internalmedicine.32.643","article-title":"Fatal pneumomediastinum in dermatomyositis without creatine kinase elevation","volume":"32","author":"Matsuda","year":"1993","journal-title":"Intern Med"},{"key":"2025090313041445000_9.1.e002770.7","doi-asserted-by":"publisher","DOI":"10.1080\/03009749950155805"},{"key":"2025090313041445000_9.1.e002770.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.24372"},{"key":"2025090313041445000_9.1.e002770.9","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00296-008-0548-1","article-title":"Pneumomediastinum in dermatomyositis itself is not a poor prognostic factor: report of a case and review of the literature","volume":"28","author":"Yoshida","year":"2008","journal-title":"Rheumatol Int"},{"key":"2025090313041445000_9.1.e002770.10","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10067-015-3001-3","article-title":"Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum","volume":"35","author":"Ma","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2025090313041445000_9.1.e002770.11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq149"},{"key":"2025090313041445000_9.1.e002770.12","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/rheumatology\/keac229","article-title":"Evaluation and validation of the prognostic value of anti-MDA5 IgG subclasses in dermatomyositis-associated interstitial lung disease","volume":"62","author":"Xu","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313041445000_9.1.e002770.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706"},{"key":"2025090313041445000_9.1.e002770.14","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-199911000-00006"},{"key":"2025090313041445000_9.1.e002770.15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/acr.22728","article-title":"Anti-Melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis","volume":"68","author":"Moghadam-Kia","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313041445000_9.1.e002770.16","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jaad.2019.05.105","article-title":"Dermatomyositis: diagnosis and treatment","volume":"82","author":"Waldman","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025090313041445000_9.1.e002770.17","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1984.00350190143024"},{"key":"2025090313041445000_9.1.e002770.18","first-page":"384","article-title":"Recurrent pneumomediastinum in adult dermatomyositis","volume":"16","author":"Cicuttini","year":"1989","journal-title":"J Rheumatol"},{"key":"2025090313041445000_9.1.e002770.19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key188"},{"key":"2025090313041445000_9.1.e002770.20","doi-asserted-by":"crossref","first-page":"S574","DOI":"10.1097\/RHU.0000000000000984","article-title":"Successful treatment for refractory interstitial lung disease and pneumomediastinum with multidisciplinary therapy including tofacitinib in a patient with anti-MDA5 antibody-positive dermatomyositis","volume":"27","author":"Kato","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"2025090313041445000_9.1.e002770.21","doi-asserted-by":"crossref","first-page":"773352","DOI":"10.3389\/fimmu.2021.773352","article-title":"Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies","volume":"12","author":"Nombel","year":"2021","journal-title":"Front Immunol"},{"key":"2025090313041445000_9.1.e002770.22","doi-asserted-by":"crossref","unstructured":"Galindo-Feria AS , Notarnicola A , Lundberg IE , et al . Aminoacyl-trna synthetases: on anti-synthetase syndrome and beyond. Front Immunol 2022;13. doi:10.3389\/fimmu.2022.866087","DOI":"10.3389\/fimmu.2022.866087"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002770","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:04:24Z","timestamp":1756929864000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,2,9]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1136\/rmdopen-2022-002770"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002770","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}